Last updated 2026-07-27
TL;DR
Sirolimus (rapamycin) binds FKBP12 and inhibits mTORC1, a nutrient-sensing pathway that slows aging processes in every model organism tested, including mice (9-14% median lifespan gains in NIA studies). It's FDA-approved for organ transplant and specific tumors, not aging. No completed human lifespan trial exists; off-label longevity dosing is extrapolated from animal data and small biomarker studies.
What is sirolimus and how is it different from rapamycin?
Sirolimus and rapamycin are the same molecule. Rapamycin is the original name, given after the compound was isolated from Streptomyces hygroscopicus in soil samples from Easter Island (Rapa Nui) in the 1970s [1]. Sirolimus is the generic drug name once it went through FDA approval. You'll see both terms used interchangeably in research papers and by longevity clinics, and that's fine, they refer to the identical chemical structure. The drug was first approved by the FDA in 1999 as Rapamune, an oral solution and tablet used to prevent organ rejection after kidney transplants [2]. It works by suppressing the immune system, which is exactly what you want after a transplant and exactly what makes longevity researchers nervous about long-term off-label use in healthy people. Two newer formulations exist: Fyarro (nab-sirolimus, an albumin-bound injectable) for a rare soft tissue tumor called malignant perivascular epithelioid cell tumor, approved in 2021, and Hyftor, a topical gel for facial angiofibromas in tuberous sclerosis complex, approved in 2022 [1] [3]. None of these approvals have anything to do with aging or lifespan. Every longevity use of sirolimus today is off-label, meaning a doctor is prescribing an FDA-approved drug for a purpose the FDA never evaluated or approved.
What does mTOR actually do in the body?
mTOR stands for mechanistic target of rapamycin (originally 'mammalian'), and it's a protein kinase that sits at the center of how cells decide whether to grow, divide, or conserve resources [1]. Think of it as a nutrient and energy sensor. When amino acids, glucose, and growth factors are abundant, mTOR activity rises and cells shift into growth mode: building proteins, dividing, storing fat. mTOR exists in two distinct protein complexes, mTORC1 and mTORC2. Sirolimus at low, intermittent doses inhibits mTORC1 fairly selectively; at higher or more continuous doses it starts hitting mTORC2 as well, and mTORC2 inhibition is linked to some of the metabolic side effects (like new-onset insulin resistance) seen in transplant patients on chronic full-dose therapy [4]. This distinction is the entire rationale behind intermittent, low-dose longevity protocols: the theory is that hitting mTORC1 hard on dosing days while giving mTORC2 time to recover in between captures the benefit while dodging the side effects. It's a plausible mechanistic story. It has not been proven in a controlled human trial.
How does sirolimus extend lifespan in mice?
This is where the actual evidence lives, and it's genuinely strong for an animal model. The National Institute on Aging's Interventions Testing Program (ITP), running since 2004 across three research sites (Jackson Laboratory, University of Michigan, University of Texas Health San Antonio), has tested dozens of compounds in genetically heterogeneous mice under identical protocols. Sirolimus is the standout. In the first ITP cohort, mice started on encapsulated rapamycin at 14 months of age (roughly equivalent to late middle age in humans) showed median lifespan increases of 9% in males and 13% in females compared to controls [5]. A later cohort started even later, at 20 months, and still saw significant extension, which matters because it suggests the drug doesn't need decades of use to work, at least in mice. Subsequent ITP rounds pushed doses higher and started treatment earlier, and effects got bigger. One report found a 23% increase in median lifespan in females at higher doses [6]. Female mice consistently respond more strongly than males across these studies, and nobody has a settled explanation why; sex-specific metabolism and hormone interactions are the leading guesses. Outside the ITP, rapamycin has extended lifespan or healthspan markers in yeast, worms (C. elegans), fruit flies (Drosophila), and shown benefits in dogs in the ongoing Dog Aging Project's rapamycin trials at the University of Washington. The consistency across species, all converging on the same nutrient-sensing pathway, is why mTOR inhibition is treated as one of the most credible levers in aging biology, not because any single study is definitive but because the signal repeats.
Is there any human evidence sirolimus extends lifespan?
No. There is no completed human trial measuring lifespan or mortality as an endpoint for sirolimus used off-label for aging. This is the single most important fact in this entire field and it bears repeating every time someone cites the mouse data as if it settles the question for people. What does exist: a small 2014 study from Novartis testing an mTOR inhibitor (RAD001, an analog of rapamycin) in elderly adults found improved response to influenza vaccination, a proxy for immune function, not a lifespan or mortality outcome . There are a handful of small, short-duration studies looking at biomarkers like periodontal health, skin aging markers, or frailty scores in people taking low-dose rapamycin, but sample sizes are small (often under 50 people) and durations are typically under a year. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), run out of AKESOgen and led by researchers including Dr. Nir Barzilai's collaborators, is an observational, crowdsourced study of people already taking rapamycin off-label; it's tracking biomarkers, not running a randomized placebo-controlled mortality endpoint. It's useful for safety signal-gathering. It is not the trial that answers whether rapamycin extends human life. Anyone claiming sirolimus is 'proven' to extend human lifespan is overstating the evidence. The honest statement is: the mouse and cross-species data are unusually consistent and mechanistically well-understood, and that's why serious researchers keep studying it, but human lifespan extension remains an extrapolation, not a demonstrated fact.
How does sirolimus mimic caloric restriction?
Caloric restriction is the oldest and most reproducible way to extend lifespan in lab animals, and it works partly by lowering mTOR activity because less food means fewer amino acids and less insulin/IGF-1 signaling to switch mTOR on . Sirolimus is often described as a 'caloric restriction mimetic' because it inhibits the same downstream node pharmacologically, without requiring the person to actually eat less. This is an appealing idea because caloric restriction is hard to sustain in real life and has its own downsides (loss of muscle mass, cold intolerance, reduced fertility in some contexts). If a drug could capture the mTOR-inhibition benefit of caloric restriction without the behavioral burden, that would be a big deal. The mouse data support the concept: rapamycin-fed mice on normal diets get some overlapping benefits with calorie-restricted mice, like reduced age-related tumor formation and better maintained tissue function [5]. But mimicking one pathway of a whole-body intervention is not the same as replicating the entire effect. Caloric restriction changes dozens of signaling pathways simultaneously (AMPK, sirtuins, insulin/IGF-1, autophagy induction through multiple routes). Sirolimus is a more surgical intervention on one node. Whether that's enough to produce comparable human benefit is unknown.
What are the real risks of off-label sirolimus for longevity?
Three risk categories show up consistently in the clinical literature, and none of them are theoretical, they're documented in transplant patients who take much higher continuous doses than longevity protocols use. Immunosuppression is the headline risk because it's the drug's approved mechanism. In transplant patients on standard doses, sirolimus increases infection risk and is associated with impaired wound healing . At the low, intermittent doses used in off-label longevity protocols (commonly once-weekly dosing), the immunosuppressive effect is intended to be much smaller, and one rationale for intermittent dosing is to let immune function recover between doses. But there's no large human safety trial confirming intermittent low-dose protocols are immunologically safe over years of use; the assumption is reasonable, it's not proven. Mouth ulcers (stomatitis) are the most commonly reported side effect even at low, intermittent longevity doses, showing up in a meaningful fraction of users in the biomarker studies and in real-world reports from people using it off-label. They're usually manageable and often improve with dose adjustment, but they're a real, near-universal nuisance, not a rare edge case. Metabolic effects are the third category and probably the least appreciated by people new to this drug. Sirolimus can raise triglycerides and LDL cholesterol and, especially with more continuous or mTORC2-affecting dosing, can worsen insulin sensitivity, sometimes described as 'rapamycin-induced' or drug-induced glucose intolerance in the transplant literature [4] . This is exactly the kind of effect that should be caught by routine bloodwork, which is why any responsible off-label protocol includes baseline and follow-up labs for lipids and fasting glucose or HbA1c.
Why do longevity protocols use intermittent, low-dose sirolimus instead of daily dosing?
Daily dosing is the transplant regimen, designed to keep blood levels continuously high enough to prevent organ rejection, and it's associated with the fuller side effect profile: more consistent immunosuppression, more consistent metabolic disruption. Intermittent dosing (commonly weekly or every-other-week) is a strategy borrowed from the mouse ITP protocols and from the mTORC1-versus-mTORC2 selectivity argument covered above. The theory, laid out by researchers like Dr. Mikhail Blagosklonny (who has published extensively on rapamycin pulse dosing) and picked up in practice by longevity-focused prescribers, is that a once-weekly higher pulse dose hits mTORC1 hard and briefly, then clears, giving mTORC2 and general immune function room to recover before the next dose [4]. Weekly dosing in mouse ITP studies is also, practically, how the drug was actually delivered in the studies producing the lifespan data, since continuous chow-based dosing effectively delivers a fluctuating, not perfectly steady, exposure. Whether weekly human dosing achieves the same mTORC1-selective, mTORC2-sparing profile that the mouse data implies is an assumption, not a directly measured fact in humans at scale. Individual variation in sirolimus clearance is also substantial; this is part of why dose-finding and blood level monitoring matter more for this drug than for something like a vitamin. If you're mapping out an actual regimen, the practical side of this (starting doses, how it's typically titrated) is covered in Sirolimus Rx dosage, and people trying to work out a specific number for their weight and goals often use a Sirolimus Rx dosage calculator as a starting point for a conversation with their prescriber, not a substitute for one.
How is sirolimus taken and administered for off-label longevity use?
For transplant use, sirolimus is FDA-labeled as an oral tablet or solution [2]. Off-label longevity use generally follows the same oral route, taken as a weekly or biweekly dose rather than daily. Some compounded formulations used by longevity-focused prescribers come as an injectable or require reconstitution rather than a manufactured tablet, which introduces its own handling and storage questions. If you're working with a compounded or injectable formulation, proper reconstitution technique matters for dosing accuracy; see how to reconstitute Sirolimus Rx for the mechanics. For people using injectable formulations specifically, injection technique and site rotation are covered in Sirolimus Rx how to inject and Sirolimus Rx injection sites. Most off-label protocols run in cycles rather than indefinitely, with periodic breaks partly to allow monitoring and reassessment and partly because there's no long-term human safety data to justify assuming indefinite use is fine; see Sirolimus Rx cycle length for how that's typically structured. None of this cycling structure comes from a completed long-term human trial; it's a precautionary framework built around the animal data and short-term human safety studies that do exist.
What does sirolimus do at the cellular level to slow aging?
Beyond the nutrient-sensing story, mTORC1 inhibition triggers autophagy, the cellular process of breaking down and recycling damaged proteins and organelles [1]. Autophagy naturally declines with age, and impaired autophagy is linked to accumulation of cellular junk implicated in several age-related diseases. By suppressing mTORC1, sirolimus releases the brake on autophagy, in theory helping cells clear out damaged components more effectively. Sirolimus also reduces cellular senescence markers in some mouse and cell-culture studies, meaning fewer cells enter the 'zombie' state where they stop dividing but keep secreting inflammatory signals (the senescence-associated secretory phenotype, or SASP) that damage surrounding tissue [5]. Reduced tumor incidence in ITP mice is thought to be partly downstream of this effect, since mTOR overactivation drives proliferation in several cancer types, which is also why sirolimus and its analogs (everolimus, temsirolimus) have separate FDA approvals as cancer therapies in specific settings. These cellular mechanisms are well documented in cell culture and animal models. Translating 'this pathway matters for aging in a mouse' into 'this dose in this human will produce this clinical benefit' is the exact gap that's currently unfilled by trial data.
Sirolimus vs. other longevity mTOR-pathway drugs: how do they compare?
| Sirolimus (rapamycin) | Direct mTORC1 inhibitor via FKBP12 binding | No completed trial | FDA-approved for transplant, Fyarro, Hyftor; longevity use off-label | |
|---|---|---|---|---|
| Everolimus | mTOR inhibitor, rapamycin analog, better oral bioavailability | No completed trial for aging; improved flu vaccine response in elderly | FDA-approved for cancer, transplant | |
| Metformin | AMPK activation, indirect mTOR suppression, lowers glucose | TAME trial (Targeting Aging with Metformin) designed but not yet fully funded/completed as of 2024 | FDA-approved for type 2 diabetes; longevity use off-label | |
| Acarbose | Alpha-glucosidase inhibitor, blunts post-meal glucose spikes | No completed human lifespan trial; extended mouse lifespan in ITP (~11% in males) [6] | FDA-approved for diabetes | Sirolimus has the strongest and most consistent animal lifespan data of anything in this table, largely because it's been the ITP's most-studied and longest-tested compound. Metformin has more real-world human safety data (it's been prescribed for type 2 diabetes since the 1990s) but its own lifespan claims rest partly on retrospective observational comparisons, not a completed dedicated longevity RCT . Neither drug has a finished human trial with mortality or lifespan as the primary endpoint. |
Several drugs act on the mTOR pathway or adjacent metabolic pathways and get compared to sirolimus in longevity discussions. Here's how the mechanism and evidence base actually stack up. | Drug | Mechanism | Human lifespan trial? | Regulatory status |
What should a longevity researcher take away from the current evidence?
The mechanistic case for mTOR inhibition is one of the better-supported ideas in aging biology: it's reproducible across yeast, worms, flies, mice, and shows a plausible signal in dogs, and it converges with the caloric restriction literature that's been accumulating for nearly a century . That's a real, unusual level of cross-species consistency, and it's why sirolimus attracts serious academic attention rather than being dismissed as another supplement fad. The honest caveat is equally real: mice are not small humans, dosing that works in a 2-year lifespan rodent doesn't map cleanly onto a species that lives 80 years, and every human data point right now is either a short biomarker study, an observational cohort, or a mechanistic inference from transplant pharmacology. Nobody has published a randomized, placebo-controlled human trial with mortality or validated lifespan-extension as its primary endpoint. Until that exists, the off-label decision is a risk-benefit judgment made with a doctor, not a settled scientific conclusion. For readers evaluating this seriously: read the ITP source data directly rather than secondhand summaries [5] [6], look at the transplant pharmacology literature for the actual side effect base rates , and treat any protocol as provisional. If you're pursuing this off-label, working with a physician who orders baseline labs, monitors lipids and glucose, and reassesses periodically is the difference between an informed experiment and a guess. Sirolimus Rx connects patients with providers who review labs and history before prescribing, and fills through a licensed pharmacy partner rather than shipping a drug with no oversight attached.
Frequently asked questions
Is sirolimus the same as rapamycin?
Yes. Rapamycin is the original compound name, isolated from Streptomyces hygroscopicus found on Easter Island in the 1970s. Sirolimus is the generic drug name used after FDA approval in 1999. They're chemically identical; the terms are used interchangeably in research and clinical settings.
Is sirolimus FDA-approved for anti-aging or longevity use?
No. Sirolimus is FDA-approved for preventing organ transplant rejection, and as Fyarro for a rare tumor type and Hyftor for a genetic skin condition. Any use for aging, lifespan extension, or longevity is off-label, meaning it's outside what the FDA evaluated and approved the drug for.
Has sirolimus been proven to extend human lifespan?
No completed human trial has measured lifespan or mortality outcomes for sirolimus. The strongest evidence is in mice, where NIA Interventions Testing Program studies show median lifespan increases of roughly 9-23% depending on dose, sex, and start age. Human data is limited to small, short biomarker studies.
How much does sirolimus extend lifespan in mice?
In the NIA Interventions Testing Program's first cohort, mice started on rapamycin at 14 months showed median lifespan increases of 9% in males and 13% in females versus untreated controls. Later cohorts using higher doses reported increases up to 23% in females, per NIA-supported ITP publications.
What is mTOR and why does sirolimus target it?
mTOR (mechanistic target of rapamycin) is a protein that senses nutrient and energy availability and controls whether cells grow, divide, or conserve resources. Sirolimus binds a protein called FKBP12, and that complex inhibits mTORC1, one of two mTOR-containing complexes, which triggers effects similar to caloric restriction.
What are the main side effects of low-dose sirolimus?
The three most documented risks are immunosuppression (increased infection susceptibility), mouth ulcers (stomatitis), which are common even at low intermittent doses, and metabolic changes including elevated triglycerides, LDL cholesterol, and reduced insulin sensitivity. These are established from transplant-dose data; long-term data at low intermittent doses is limited.
Why do people take sirolimus weekly instead of daily for longevity?
Daily dosing is the transplant regimen and carries the fuller side effect profile. Weekly or intermittent dosing is theorized to inhibit mTORC1 (the target linked to longevity effects) while sparing mTORC2 (linked to metabolic side effects), letting immune function recover between doses. This selectivity theory is plausible but not confirmed in large human trials.
Does sirolimus mimic caloric restriction?
Partially. Caloric restriction lowers mTOR activity along with several other pathways (AMPK, insulin/IGF-1, sirtuins). Sirolimus inhibits mTORC1 specifically and pharmacologically, without requiring reduced food intake, and produces some overlapping benefits in mice, but it isn't a complete substitute for the whole-body effects of actual caloric restriction.
What is the NIA Interventions Testing Program?
It's a National Institute on Aging-funded research program, running since 2004 across Jackson Laboratory, University of Michigan, and University of Texas Health San Antonio, that tests compounds for lifespan effects in genetically diverse mice using standardized protocols. Sirolimus is its most consistently positive finding across multiple test cohorts.
How is sirolimus different from everolimus?
Everolimus is a rapamycin analog (a 'rapalog') with modified chemistry for better oral absorption. Both inhibit mTORC1 through the same FKBP12-binding mechanism. Everolimus is FDA-approved for certain cancers and transplant rejection; like sirolimus, it has no completed human lifespan trial and no FDA approval for aging.
Is metformin a better-studied longevity option than sirolimus?
Metformin has more decades of human safety data since it's been prescribed for type 2 diabetes since the 1990s, but its longevity case rests mostly on observational comparisons, not a completed dedicated trial. Sirolimus has stronger, more consistent lifespan-extension data in animal models. Neither has a finished human lifespan RCT.
Can sirolimus cause immunosuppression at low longevity doses?
Immunosuppression is sirolimus's core approved mechanism, so some degree of immune effect is expected at any dose. Low, intermittent dosing is designed to minimize this compared to daily transplant regimens, but there's no large-scale human trial confirming intermittent low-dose protocols are free of meaningful immune suppression over years of use.
Do I need blood monitoring while taking sirolimus off-label?
Given documented effects on lipids, glucose, and immune function at treatment doses, routine bloodwork (lipid panel, fasting glucose or HbA1c, and periodic sirolimus blood levels) is standard practice for responsible off-label use. This monitoring is how a prescriber catches metabolic or immune changes before they become clinically significant.
Sources
- NIH National Institute on Aging, rapamycin research background: Rapamycin was isolated from Streptomyces hygroscopicus found in soil from Easter Island
- FDA, Hyftor approval: Hyftor (topical sirolimus gel) was FDA-approved in 2022 for facial angiofibroma in tuberous sclerosis complex
- Blagosklonny, mTOR pulse-dosing hypothesis literature (Oncotarget/Aging journal): Intermittent dosing is theorized to selectively inhibit mTORC1 while sparing mTORC2-linked metabolic effects
- Miller et al., Aging Cell / NIA Interventions Testing Program reports: Higher-dose rapamycin cohorts extended median lifespan up to 23% in female mice; acarbose extended male lifespan in ITP studies
- Mannick et al., Science Translational Medicine (2014): An mTOR inhibitor (RAD001) improved influenza vaccine response in elderly adults in a placebo-controlled trial
- NIH National Institute on Aging, caloric restriction and aging research: Caloric restriction is among the most reproducible lifespan-extending interventions in animal models and works partly through reduced mTOR/insulin-IGF-1 signaling